[ Impact of CCND1 A870 G polymorphism on <font color="blue">acute_2</font> <font color="blue">adverse_2</font> <font color="blue">events_2</font> in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ] . 
<br>
<br> OBJECTIVE The purpose of this study was to investigate the <font color="blue">association_1</font> <font color="blue">between_1</font> <font color="blue">single_1</font> <font color="blue">nucleotide_1</font> <font color="blue">polymorphism_1</font> <font color="blue">(_1</font> <font color="blue">SNP_1</font> <font color="blue">)_1</font> <font color="blue">of_1</font> <font color="blue">CCND1_1</font> <font color="blue">A870_1</font> <font color="blue">G_1</font> <font color="blue">and_1</font> <font color="blue">acute_2</font> <font color="blue">adverse_2</font> <font color="blue">events_2</font> <font color="blue">(_2</font> <font color="blue">AEs_2</font> <font color="blue">)_2</font> in postoperative rectal cancer patients who received capecitabine - based postoperative chemoradiotherapy ( CRT ) . 
<br> METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin were accumulated and prostectively studied in this study . The patients were randomly divided into two groups . Two hundred and twenty - eight patients were treated with concurrent capecitabine and radiotherapy ( Cap - CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap - Oxa - CRT ) . <font color="blue">Adverse_2</font> <font color="blue">events_2</font> <font color="blue">were_1</font> <font color="blue">graded_1</font> <font color="blue">according_1</font> <font color="blue">to_1</font> <font color="blue">the_1</font> <font color="blue">Common_1</font> <font color="blue">Terminology_1</font> <font color="blue">Criteria_1</font> <font color="blue">for_1</font> <font color="blue">Adverse_1</font> <font color="blue">Events_1</font> <font color="blue">,_1</font> <font color="blue">v._1</font> <font color="blue">3.0_1</font> <font color="blue">(_1</font> <font color="blue">CTCAE_1</font> <font color="blue">v3.0_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> The genotype of CCND1 A870 G in the patients was detected by polymerase chain reaction - based restriction fragment length polymorphism ( PCR - RFLP ) analysis . The associations between the SNP and <font color="blue">acute_1</font> <font color="blue">AEs_1</font> were indicated by odds ratios ( ORs ) and 95% confidence intervals ( CIs ) , which were computed with logistic regression model . 
<br> RESULTS <font color="blue">A_1</font> <font color="blue">total_1</font> <font color="blue">of_1</font> <font color="blue">136_1</font> <font color="blue">patients_1</font> <font color="blue">presented_1</font> <font color="blue">severe_1</font> <font color="blue">AEs_2</font> <font color="blue">._2</font> <font color="blue">Among_1</font> <font color="blue">them_1</font> <font color="blue">the_1</font> <font color="blue">frequencies_1</font> <font color="blue">of_1</font> <font color="blue">the_1</font> <font color="blue">three_1</font> <font color="blue">genotypes_1</font> <font color="blue">GG_1</font> <font color="blue">,_1</font> <font color="blue">GA_1</font> <font color="blue">and_1</font> <font color="blue">AA_1</font> <font color="blue">were_1</font> <font color="blue">16.9%_1</font> <font color="blue">,_1</font> <font color="blue">50.7%_1</font> <font color="blue">and_1</font> <font color="blue">32.4%_1</font> <font color="blue">,_1</font> <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">24.6%_1</font> <font color="blue">,_1</font> <font color="blue">48.1%_1</font> <font color="blue">and_1</font> <font color="blue">27.3%_1</font> <font color="blue">,_1</font> <font color="blue">respectively_1</font> <font color="blue">,_1</font> <font color="blue">among_1</font> <font color="blue">the_1</font> <font color="blue">patients_1</font> <font color="blue">without_1</font> <font color="blue">severe_1</font> <font color="blue">AEs_1</font> <font color="blue">._1</font> <font color="blue">Diarrhea_2</font> <font color="blue">was_2</font> <font color="blue">the_2</font> <font color="blue">most_2</font> <font color="blue">common_2</font> <font color="blue">AE_2</font> <font color="blue">,_2</font> <font color="blue">and_1</font> <font color="blue">severe_1</font> <font color="blue">diarrhea_1</font> <font color="blue">occurred_1</font> <font color="blue">in_1</font> <font color="blue">109_1</font> <font color="blue">patients_1</font> <font color="blue">._1</font> <font color="blue">The_1</font> <font color="blue">frequencies_1</font> <font color="blue">of_1</font> <font color="blue">the_1</font> <font color="blue">three_1</font> <font color="blue">genotypes_1</font> <font color="blue">GG_1</font> <font color="blue">,_1</font> <font color="blue">GA_1</font> <font color="blue">and_1</font> <font color="blue">AA_1</font> <font color="blue">were_1</font> <font color="blue">15.6%_1</font> <font color="blue">,_1</font> <font color="blue">47.7%_1</font> <font color="blue">and_1</font> <font color="blue">36.7%_1</font> <font color="blue">among_1</font> <font color="blue">these_1</font> <font color="blue">patients_1</font> <font color="blue">,_1</font> <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">24.4%_1</font> <font color="blue">,_1</font> <font color="blue">49.5%_1</font> <font color="blue">and_1</font> <font color="blue">26.1%_1</font> <font color="blue">,_1</font> <font color="blue">respectively_1</font> <font color="blue">,_1</font> <font color="blue">among_1</font> <font color="blue">patients_1</font> <font color="blue">without_1</font> <font color="blue">severe_1</font> <font color="blue">diarrhea_1</font> <font color="blue">._1</font> Multivariate logistic regression analysis showed a 1.66-fold increased <font color="blue">risk_1</font> <font color="blue">for_1</font> <font color="blue">severe_2</font> <font color="blue">diarrhea_2</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">AA_1</font> <font color="blue">genotype_1</font> <font color="blue">(_1</font> <font color="blue">95%CI_1</font> <font color="blue">1.03_1</font> <font color="blue">-_1</font> <font color="blue">2.67_1</font> <font color="blue">,_1</font> <font color="blue">P_1</font> <font color="blue">=_1</font> <font color="blue">0.038_1</font> <font color="blue">)_1</font> <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">the_1</font> <font color="blue">cases_1</font> <font color="blue">with_1</font> <font color="blue">GG_1</font> <font color="blue">or_1</font> <font color="blue">GA_1</font> <font color="blue">genotypes_1</font> <font color="blue">._1</font> Stratified analysis showed that in the Cap - Oxa - CRT group , patients with AA genotype showed a 2.34-fold <font color="blue">increased_1</font> <font color="blue">risk_1</font> <font color="blue">for_1</font> <font color="blue">severe_2</font> <font color="blue">diarrhea_2</font> ( 95%CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap - CRT group , the <font color="blue">SNP_1</font> <font color="blue">was_1</font> <font color="blue">not_1</font> <font color="blue">associated_1</font> <font color="blue">with_1</font> <font color="blue">the_1</font> <font color="blue">risk_1</font> <font color="blue">of_1</font> <font color="blue">severe_2</font> <font color="blue">diarrhea_2</font> <font color="blue">._2</font> <font color="blue">
<br>_1</font> CONCLUSIONS <font color="blue">The_1</font> <font color="blue">genetic_1</font> <font color="blue">polymorphism_1</font> <font color="blue">of_1</font> <font color="blue">CCND1_1</font> <font color="blue">A870_1</font> <font color="blue">G_1</font> <font color="blue">might_1</font> <font color="blue">be_1</font> <font color="blue">a_1</font> <font color="blue">potential_1</font> <font color="blue">biomarker_1</font> <font color="blue">for_1</font> <font color="blue">predicting_1</font> <font color="blue">acute_2</font> <font color="blue">AEs_2</font> <font color="blue">in_1</font> <font color="blue">postoperative_1</font> <font color="blue">stage_1</font> <font color="blue">II_1</font> <font color="blue">and_1</font> <font color="blue">III_1</font> <font color="blue">rectal_1</font> <font color="blue">cancer_1</font> <font color="blue">patients_1</font> <font color="blue">treated_1</font> <font color="blue">with_1</font> <font color="blue">adjuvant_1</font> <font color="blue">concurrent_1</font> <font color="blue">chemoradiotherapy_1</font> <font color="blue">of_1</font> <font color="blue">capecitabine_1</font> <font color="blue">and_1</font> <font color="blue">oxaliplatin_1</font> <font color="blue">._1</font> <font color="blue">
<br>
<br>_1</font>